Finch Therapeutics

Finch Therapeutics describes itself as an early pioneer in the microbiome field and states that it has established a portfolio of innovative microbiome assets with potential applicability to a wide range of product strategies and therapeutic areas. Its portfolio is described as designed with insights from human microbiota transplantation studies, and the company states it has a robust intellectual property estate. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent C. difficile and to focus on realizing the value of its IP estate and other assets. The company announced delisting from Nasdaq and SEC deregistration in October 2024, and announced the resignation of its Chief Financial Officer in January 2025. Its leadership team is described as seasoned biotech executives and pioneers in the microbiome field, and Matthew P. Blischak, JD serves as Chief Executive Officer.

Finch Therapeutics describes itself as an early pioneer in the microbiome field and states that it has established a portfolio of innovative microbiome assets with potential applicability to a wide range of product strategies and therapeutic areas. Its portfolio is described as designed with insights from human microbiota transplantation studies. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent C. difficile and focus on realizing the value of its IP estate and other assets. The company announced delisting from Nasdaq and SEC deregistration in October 2024, and announced the resignation of its Chief Financial Officer in January 2025.

An early pioneer in the microbiome field with a portfolio of innovative microbiome assets.

• CP101

  An oral microbiome drug studied in recurrent C. difficile infection, including a Phase 3 trial and the PRISM3 trial.

1. 1Home — Finch Therapeuticsfinchtherapeutics.com
2. 2About — Finch Therapeuticsfinchtherapeutics.com
3. 3Finch Therapeutics (United States)wikidata.org